• Bloomberg


Roche Holding AG decided against bidding for the almost 40 percent of drugmaker Chugai Pharmaceutical Co. that it doesn’t already own and is instead focused on its $8.3 billion acquisition of InterMune Inc., according to a person familiar with the matter.

As it worked on the InterMune deal, announced Sunday, Roche was also considering a bid for Chugai, the person said, asking not to be identified because the talks were private. The Swiss company has decided against pursuing a deal with Chugai for now after the Japanese company’s management signaled opposition to a bid, the person said.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.